RESUMO
This study reports the effects of metoclopramide (10 mg i.v.) on intravascular esophageal variceal pressure in 12 patients with alcoholic cirrhosis. The esophageal variceal pressure was measured by the direct variceal puncture technique. Metoclopramide caused a reduction in the variceal pressure in 10 out of 12 patients; overall, there was a decrease from 21.5 +/- 5.0 mmHg to 14.0 +/- 3.4 mmHg (p < 0.001). In conclusion, intravenous metoclopramide, which increases lower esophageal sphincter pressure, significantly decreases intravascular variceal pressure in cirrhotic patients.
Assuntos
Varizes Esofágicas e Gástricas/tratamento farmacológico , Hemorragia Gastrointestinal/tratamento farmacológico , Metoclopramida/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Varizes Esofágicas e Gástricas/etiologia , Junção Esofagogástrica/efeitos dos fármacos , Feminino , Hemorragia Gastrointestinal/etiologia , Humanos , Cirrose Hepática Alcoólica/complicações , Masculino , Pessoa de Meia-IdadeRESUMO
Lower esophageal sphincter (LES) pressure was measured in 7 cirrhotic patients with massive ascites, before and after paracentesis. The mean LES pressure was 19.8 +/- 2.2 SEM mm Hg before and 16.3 +/- 1.4 SEM mm Hg after paracentesis (p less than 0.05). It is concluded that cirrhotic patients with massive ascites are protected from reflux esophagitis by having an increased LES pressure.
Assuntos
Ascite/complicações , Junção Esofagogástrica/fisiopatologia , Cirrose Hepática/complicações , Adulto , Esofagite Péptica/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pressão , SucçãoRESUMO
The term "biloma" describes an intra-abdominal bile collection secondary to traumatic or iatrogenic injury of the biliary tree. We present a case of biloma treated by guided percutaneous needle aspiration.
Assuntos
Bile , Hepatopatias/diagnóstico , Doenças Peritoneais/diagnóstico , Punções/métodos , Sucção/métodos , Ultrassonografia , Feminino , Humanos , Fígado/patologia , Hepatopatias/etiologia , Hepatopatias/terapia , Pessoa de Meia-Idade , Cavidade Peritoneal/patologia , Doenças Peritoneais/etiologia , Doenças Peritoneais/terapiaRESUMO
Twenty-eight patients with histologically proven reflux esophagitis were randomly allocated to receive either De-Nol (tripotassium dicitrate bismuthate) or placebo for three weeks. Significant decreases in symptoms frequency and severity were noted in De-Nol group comparing with placebo group (p less than 0.01). Objective improvement in esophageal endoscopic appearance was obtained in 78.5% of the patients treated with De-Nol and only in 14.2% of those receiving placebo. De-Nol appears to be an effective drug in the treatment of reflux esophagitis, but this should be confirmed by further studies.